What is Vincerx Pharma Inc's earnings per share (EPS)?

Vincerx Pharma Inc (VINC) reported diluted earnings per share of $-15.85 for fiscal year 2024. This represents a 58.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Vincerx Pharma Inc Financials

VINC

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2025 Currency USD FYE December

This page shows Vincerx Pharma Inc (VINC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Vincerx Pharma Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.87x

For every $1 of reported earnings, Vincerx Pharma Inc generates $0.87 in operating cash flow (-$26.1M OCF vs -$30.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$31.4M

YoY+26.2%

Vincerx Pharma Inc's EBITDA was -$31.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 26.2% from the prior year.

Net Income

-$30.1M

YoY+25.1%

Vincerx Pharma Inc reported -$30.1M in net income in fiscal year 2024. This represents an increase of 25.1% from the prior year.

EPS (Diluted)

$-15.85

YoY+58.0%

Vincerx Pharma Inc earned $-15.85 per diluted share (EPS) in fiscal year 2024. This represents an increase of 58.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$5.0M

YoY-61.0%

Vincerx Pharma Inc held $5.0M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

YoY+109.2%

Vincerx Pharma Inc had 2M shares outstanding in fiscal year 2024. This represents an increase of 109.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-1104.0%

YoY-746.2pp

Vincerx Pharma Inc's ROE was -1104.0% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 746.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$15.5M

YoY-46.6%

Vincerx Pharma Inc invested $15.5M in research and development in fiscal year 2024. This represents a decrease of 46.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

VINC Income Statement

Metric	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$15.5M-46.6%	$29.0M-41.9%	$49.8M+24.3%	$40.1M+1794.2%	$2.1M
SG&A Expenses	$16.0M+17.2%	$13.6M-27.8%	$18.9M-16.3%	$22.6M+527.4%	$3.6M
Operating Income	-$31.5M+26.2%	-$42.6M+40.1%	-$71.2M-13.6%	-$62.7M-484.8%	-$10.7M
Interest Expense	N/A	N/A	N/A	$8K0.0%	$8K
Income Tax	N/A	N/A	N/A	N/A	$812
Net Income	-$30.1M+25.1%	-$40.2M+36.2%	-$63.0M-60.2%	-$39.3M-136.5%	-$16.6M
EPS (Diluted)	$-15.85+58.0%	$-37.72	$-3.00-31.0%	$-2.29	N/A

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.0M	N/A	$3.9M+4.1%	$3.8M-17.6%	$4.6M	N/A	$6.1M-26.0%	$8.2M
SG&A Expenses	$2.3M	N/A	$3.9M+7.6%	$3.6M+23.6%	$2.9M	N/A	$3.5M-8.0%	$3.8M
Operating Income	-$3.3M	N/A	-$7.8M-5.8%	-$7.4M+1.5%	-$7.5M	N/A	-$9.6M+20.3%	-$12.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.0M	N/A	-$7.8M-333.8%	-$1.8M+85.5%	-$12.4M	N/A	-$9.0M+22.0%	-$11.6M
EPS (Diluted)	$-1.40	N/A	$-15.85-31600.0%	$-0.05+99.6%	$-11.46	N/A	$-37.72-6885.2%	$-0.54

VINC Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20
Total Assets	$8.0M-56.1%	$18.2M-69.3%	$59.3M-49.6%	$117.7M+86.2%	$63.2M
Current Assets	$6.4M-56.5%	$14.7M-73.7%	$56.0M-50.0%	$111.8M+77.2%	$63.1M
Cash & Equivalents	$5.0M-61.0%	$12.8M+9.6%	$11.7M-89.5%	$111.5M+80.4%	$61.8M
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.3M-24.5%	$7.0M-39.8%	$11.6M-33.1%	$17.4M-54.1%	$37.8M
Current Liabilities	$5.3M-5.8%	$5.6M-38.8%	$9.2M-34.2%	$13.9M-63.2%	$37.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.7M-75.7%	$11.2M-76.5%	$47.7M-52.5%	$100.3M+295.3%	$25.4M
Retained Earnings	-$189.2M-18.9%	-$159.1M-33.8%	-$119.0M-112.5%	-$56.0M-235.9%	-$16.7M

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Total Assets	$4.7M-41.5%	$8.0M-46.4%	$14.9M-30.6%	$21.5M+94.2%	$11.1M-39.2%	$18.2M-30.7%	$26.3M-25.5%	$35.3M
Current Assets	$4.7M-26.9%	$6.4M-45.4%	$11.7M-35.7%	$18.3M+138.2%	$7.7M-47.9%	$14.7M-35.4%	$22.8M-28.3%	$31.8M
Cash & Equivalents	$4.4M-11.0%	$5.0M+69.5%	$2.9M-62.9%	$7.9M+55.0%	$5.1M-60.0%	$12.8M-15.2%	$15.1M+125.8%	$6.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.6M-50.4%	$5.3M-9.6%	$5.8M-3.9%	$6.1M-48.1%	$11.7M+67.3%	$7.0M-33.6%	$10.5M-5.4%	$11.1M
Current Liabilities	$2.6M-50.4%	$5.3M-2.6%	$5.4M+1.7%	$5.3M-49.9%	$10.6M+89.7%	$5.6M-36.6%	$8.8M-3.4%	$9.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.1M-24.2%	$2.7M-70.1%	$9.1M-41.0%	$15.4M+2583.6%	-$622K-105.5%	$11.2M-28.7%	$15.7M-34.8%	$24.1M
Retained Earnings	-$194.2M-2.6%	-$189.2M-4.4%	-$181.2M-4.5%	-$173.3M-1.1%	-$171.5M-7.8%	-$159.1M-1.6%	-$156.5M-6.6%	-$146.8M

VINC Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$26.1M+35.4%	-$40.5M+32.1%	-$59.6M-78.4%	-$33.4M-1365.6%	-$2.3M
Capital Expenditures	N/A	N/A	$0-100.0%	$258K	N/A
Free Cash Flow	N/A	N/A	-$59.6M-77.1%	-$33.7M	N/A
Investing Cash Flow	$212K-99.5%	$41.5M+202.3%	-$40.6M-671.7%	-$5.3M+92.0%	-$65.6M
Financing Cash Flow	$18.0M+15682.5%	$114K-59.3%	$280K-99.7%	$88.5M+38.1%	$64.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Operating Cash Flow	-$4.5M+27.9%	-$6.2M+3.1%	-$6.4M-9.5%	-$5.8M+24.7%	-$7.7M+3.5%	-$8.0M-20.7%	-$6.6M+47.7%	-$12.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$7.2M+422.2%	$1.4M+116.5%	-$8.3M	$0-100.0%	$5.8M-61.8%	$15.1M+1.7%	$14.8M
Financing Cash Flow	$3.9M+291.5%	$985K	$0-100.0%	$17.0M+339940.0%	$5K-72.2%	$18K	$0-100.0%	$93K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VINC Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A
Return on Equity	-1104.0%-746.2pp	-357.8%-225.7pp	-132.1%-93.0pp	-39.2%+26.3pp	-65.5%
Return on Assets	-375.7%-155.2pp	-220.4%-114.2pp	-106.2%-72.8pp	-33.4%-7.1pp	-26.3%
Current Ratio	1.21-1.4	2.63-3.5	6.11-1.9	8.04+6.4	1.67
Debt-to-Equity	1.94+1.3	0.62+0.4	0.24+0.1	0.17-1.3	1.49
FCF Margin	N/A	N/A	N/A	N/A	N/A

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-242.0%	N/A	-86.1%-74.4pp	-11.7%	N/A	N/A	-57.2%-9.4pp	-47.9%
Return on Assets	-106.7%	N/A	-52.5%-44.1pp	-8.4%+103.7pp	-112.1%	N/A	-34.3%-1.5pp	-32.7%
Current Ratio	1.79+0.6	1.21-1.0	2.17-1.3	3.43+2.7	0.72-1.9	2.63+0.0	2.58-0.9	3.47
Debt-to-Equity	1.27-0.7	1.94+1.3	0.64+0.2	0.39+19.2	-18.82-19.4	0.62-0.0	0.67+0.2	0.46
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Trevena Inc TRVN

$1.3M

Panbela Therapeutics Inc PBLA

$243K

Scorpius Holdings SCPX

$1.5M

Altamira Therapeutics Ltd CYTOF

$286K

Respirerx Pharma RSPI

$849K

Frequently Asked Questions

Is Vincerx Pharma Inc profitable?

No, Vincerx Pharma Inc (VINC) reported a net income of -$30.1M in fiscal year 2024.

What is Vincerx Pharma Inc's EBITDA?

Vincerx Pharma Inc (VINC) had EBITDA of -$31.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Vincerx Pharma Inc's return on equity (ROE)?

Vincerx Pharma Inc (VINC) has a return on equity of -1104.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Vincerx Pharma Inc's operating cash flow?

Vincerx Pharma Inc (VINC) generated -$26.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Vincerx Pharma Inc's total assets?

Vincerx Pharma Inc (VINC) had $8.0M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Vincerx Pharma Inc spend on research and development?

Vincerx Pharma Inc (VINC) invested $15.5M in research and development during fiscal year 2024.

How many shares does Vincerx Pharma Inc have outstanding?

Vincerx Pharma Inc (VINC) had 2M shares outstanding as of fiscal year 2024.

What is Vincerx Pharma Inc's current ratio?

Vincerx Pharma Inc (VINC) had a current ratio of 1.21 as of fiscal year 2024, which is considered adequate.

What is Vincerx Pharma Inc's debt-to-equity ratio?

Vincerx Pharma Inc (VINC) had a debt-to-equity ratio of 1.94 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Vincerx Pharma Inc's return on assets (ROA)?

Vincerx Pharma Inc (VINC) had a return on assets of -375.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Vincerx Pharma Inc's cash runway?

Based on fiscal year 2024 data, Vincerx Pharma Inc (VINC) had $5.0M in cash against an annual operating cash burn of $26.1M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Vincerx Pharma Inc's Piotroski F-Score?

Vincerx Pharma Inc (VINC) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Vincerx Pharma Inc's earnings high quality?

Vincerx Pharma Inc (VINC) has an earnings quality ratio of 0.87x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.